USFDA gives final nod to Alembic Pharmaceutical’s cardiac disorder tablets | The Financial Express

USFDA gives final nod to Alembic Pharmaceutical’s cardiac disorder tablets

The drug is indicated for the management of Vasospastic Angina, Chronic Stable Angina (Classical Effort-Associated Angina), and hypertension.

USFDA gives final nod to Alembic Pharmaceutical’s cardiac disorder tablets
GlobalData’s research reveals that North America accounted for 51.7% of cardiomyopathy drug sales in the 68M in 2021 and is expected to account for 54.2% in 2031. (File)

Alembic Pharmaceuticals Limited on Monday announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg.

According to the company’s press statement, the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Procardia XL Extended-Release Tablets, 30 mg, 60 mg and 90 mg, of Pfizer Inc. Nifedipine Extended-Release Tablets.

The drug is indicated for the management of Vasospastic Angina, Chronic Stable Angina (Classical Effort-Associated Angina), and hypertension.

Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg, have an estimated market size of US$ 56 million for twelve months ending Sep 2022 according to IQVIA.

Alembic has a cumulative total of 177 ANDA approvals (153 final approvals and 24 tentative approvals) from the USFDA.

ALSO READ | Alembic Pharma Q2 PAT dips 19% Y-O-Y; Revenue up 14% to Rs. 1475 crores

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 21-11-2022 at 14:52 IST